P53 in breast cancer: Mutation and countermeasures

Frontiers in Bioscience

Volumn 12, Issue 11, 2007, Pages 4168-4178

  Kumar, Sumit ^a   Walia, Vijay ^a   Ray, Maria ^a   Elble, Randolph C ^a  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; MDM2; Mutation; Nutlin; P53; Review; Therapy

Indexed keywords

MAMMALIA;

BREAST TUMOR; FEMALE; GENE THERAPY; GENETICS; HUMAN; MUTATION; REVIEW; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; FEMALE; GENE THERAPY; GENES, P53; HUMANS; MUTATION;

EID: 34347233807     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2378     Document Type: Article

References (150)

1. L. A. Donehower, M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992)
2. M. Robinson, P. Jiang, J. Cui, J. Li, Y. Wang, M. Swaroop, S. Madore, T. S. Lawrence, and Y. Sun: Global genechip profiling to identify genes responsive to p53-induced growth arrest and apoptosis in human lung carcinoma cells. Cancer Biol. Ther. 2, 406-415 (2003)
3. E. M. Hammond, D. J. Mandell, A. Salim, A. J. Krieg, T. M. Johnson, H. A. Shirazi, L. D. Attardi, and A. J. Giaccia: Genome-wide analysis of p53 under hypoxic conditions. Mol. Cell Biol. 26, 3492-3504 (2006)
4. C. L. Wei, Q. Wu, V. B. Vega, K. P. Chiu, P. Ng, T. Zhang, A. Shahab, H. C. Yong, Y. Fu, Z. Weng, J. Liu, X. D. Zhao, J. L. Chew, Y. L. Lee, V. A. Kuznetsov, W. K. Sung, L. D. Miller, B. Lim, E. T. Liu, Q. Yu, H. H. Ng, and Y. Ruan: A global map of p53 transcription-factor binding sites in the human genome. Cell 124, 207-219 (2006) (Pubitemid 43069320)
5. C. H. Arrowsmith: Structure and function in the p53 family. Cell Death. Differ. 6, 1169-1173 (1999) (Pubitemid 30047893)
6. C. L. Brooks and W. Gu: Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15, 164-171 (2003) (Pubitemid 36332191)
7. L. Kaustov, G. S. Yi, A. Ayed, E. Bochkareva, A. Bochkarev, and C. H. Arrowsmith: p53 transcriptional activation domain: a molecular chameleon? Cell Cycle 5, 489-494 (2006) (Pubitemid 43340524)
8. C. L. Brooks and W. Gu: Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr. Opin. Cell Biol. 15, 164-171 (2003) (Pubitemid 36332191)
9. Y. Kawaguchi, A. Ito, E. Appella, and T. P. Yao: Charge modification at multiple C-terminal lysine residues regulates p53 oligomerization and its nucleus-cytoplasm trafficking. J. Biol. Chem. 281, 1394-1400 (2006)
10. D. Schmidt and S. Muller: Members of the PIAS family act as SUMO ligases for c-Jun. and p53 and repress p53 activity. Proc. Natl. Acad. Sci. U. S. A 99, 2872-2877 (2002) (Pubitemid 34240553)
11. S. Chuikov, J. K. Kurash, J. R. Wilson, B. Xiao, N. Justin, G. S. Ivanov, K. McKinney, P. Tempst, C. Prives, S. J. Gamblin, N. A. Barlev, and D. Reinberg: Regulation of p53 activity through lysine methylation. Nature 432, 353-360 (2004) (Pubitemid 39551664)
12. D. P. Xirodimas, M. K. Saville, J. C. Bourdon, R. T. Hay, and D. P. Lane: Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118, 83-97 (2004) (Pubitemid 38902816)
13. R. Honda, H. Tanaka, and H. Yasuda: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27 (1997) (Pubitemid 28037193)
14. X. Wu, J. H. Bayle, D. Olson, and A. J. Levine: The p53-mdm-2 autoregulatory feedback loop. Genes Dev. 7, 1126-1132 (1993) (Pubitemid 23207405)
15. C. J. Sherr: Tumor surveillance via the ARF-p53 pathway. Genes Dev. 12, 2984-2991 (1998) (Pubitemid 28469300)
16. B. Eymin, L. Karayan, P. Seite, C. Brambilla, E. Brambilla, C. J. Larsen, and S. Gazzeri: Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 20, 1033-1041 (2001) (Pubitemid 32238852)
17. T. Kamijo, F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. J. Sherr: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659 (1997) (Pubitemid 27513656)
18. J. D. Weber, J. R. Jeffers, J. E. Rehg, D. H. Randle, G. Lozano, M. F. Roussel, C. J. Sherr, and G. P. Zambetti: p53-independent functions of the p19 (ARF) tumor suppressor. Genes Dev. 14, 2358-2365 (2000)
19. S. Gazzeri, V. Della, V. L. Chaussade, C. Brambilla, C. J. Larsen, and E. Brambilla: The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer. Cancer Res. 58, 3926-3931 (1998) (Pubitemid 28405650)
20. B. Quesnel, C. Preudhomme, J. Fournier, P. Fenaux, and J. P. Peyrat: MDM2 gene amplification in human breast cancer. Eur. J. Cancer 30 A, 982-984 (1994) (Pubitemid 24256248)
21. F. Toledo, K. A. Krummel, C. J. Lee, C. W. Liu, L. W. Rodewald, M. Tang, and G. M. Wahl: A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9, 273-285 (2006)
22. S. Francoz, P. Froment, S. Bogaerts, C. S. De, M. Maetens, G. Doumont, E. Bellefroid, and J. C. Marine: Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad. Sci. U. S. A 103, 3232-3237 (2006) (Pubitemid 43346453)
23. F. Toledo, K. A. Krummel, C. J. Lee, C. W. Liu, L. W. Rodewald, M. Tang, and G. M. Wahl: A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 9, 273-285 (2006)
24. W. P. Roos and B. Kaina: DNA damage-induced cell death by apoptosis. Trends Mol. Med. 12, 440-450 (2006) (Pubitemid 44291571)
25. P. A. Wingo, T. Tong, and S. Bolden: Cancer statistics, 1995. CA Cancer J. Clin. 45, 8-30 (1995)
26. B. Newman, H. Mu, L. M. Butler, R. C. Millikan, P. G. Moorman, and M. C. King: Frequency of breast cancer attributable to BRCA1 in a population-based series of American women. JAMA 279, 915-921 (1998) (Pubitemid 28136080)
27. F. P. Li and J. F. Fraumeni, Jr.: Prospective study of a family cancer syndrome. JAMA 247, 2692-2694 (1982) (Pubitemid 12105070)
28. T. Soussi, S. Kato, P. P. Levy, and C. Ishioka: Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum. Mutat. 25, 6-17 (2005) (Pubitemid 40075908)
29. S. Banin, L. Moyal, S. Shieh, Y. Taya, C. W. Anderson, L. Chessa, N. I. Smorodinsky, C. Prives, Y. Reiss, Y. Shiloh, and Y. Ziv: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281, 1674-1677 (1998)
30. C. E. Canman, D. S. Lim, K. A. Cimprich, Y. Taya, K. Tamai, K. Sakaguchi, E. Appella, M. B. Kastan, and J. D. Siliciano: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281, 1677-1679 (1998) (Pubitemid 28435584)
31. H. Nevanlinna and J. Bartek: The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25, 5912-5919 (2006) (Pubitemid 44453447)
32. P. Y. Zeng and S. L. Berger: LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation. Cancer Res. 66, 10701-10708 (2006) (Pubitemid 44876965)
33. A. Hemminki, D. Markie, I. Tomlinson, E. Avizienyte, S. Roth, A. Loukola, G. Bignell, W. Warren, M. Aminoff, P. Hoglund, H. Jarvinen, P. Kristo, K. Pelin, M. Ridanpaa, R. Salovaara, T. Toro, W. Bodmer, S. Olschwang, A. S. Olsen, M. R. Stratton, C. A. de la, and L. A. Aaltonen: A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391, 184-187 (1998) (Pubitemid 28092478)
34. D. E. Jenne, H. Reimann, J. Nezu, W. Friedel, S. Loff, R. Jeschke, O. Muller, W. Back, and M. Zimmer: Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 18, 38-43 (1998) (Pubitemid 28027876)
35. H. Lai, L. Lin, M. Nadji, S. Lai, E. Trapido, and L. Meng: Mutations in the p53 tumor suppressor gene and early onset breast cancer. Cancer Biol. Ther. 1, 31-36 (2002)
36. M. Olivier, S. P. Hussain, F. C. Caron de, P. Hainaut, and C. C. Harris: TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci. Publ., 247-270 (2004)
37. A. Willis, E. J. Jung, T. Wakefield, and X. Chen: Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23, 2330-2338 (2004) (Pubitemid 38496788)
38. P. Campomenosi, P. Monti, A. Aprile, A. Abbondandolo, T. Frebourg, B. Gold, T. Crook, A. Inga, M. A. Resnick, R. Iggo, and G. Fronza: p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20, 3573-3579 (2001) (Pubitemid 32619411)
39. P. Campomenosi, P. Monti, A. Aprile, A. Abbondandolo, T. Frebourg, B. Gold, T. Crook, A. Inga, M. A. Resnick, R. Iggo, and G. Fronza: p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements. Oncogene 20, 3573-3579 (2001) (Pubitemid 32619411)
40. S. Rowan, R. L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, and K. H. Vousden: Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J. 15, 827-838 (1996) (Pubitemid 26064289)
41. G. Liu, J. M. Parant, G. Lang, P. Chau, A. Chavez-Reyes, A. K. El-Naggar, A. Multani, S. Chang, and G. Lozano: Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat. Genet. 36, 63-68 (2004) (Pubitemid 38056209)
42. A. L. Borresen-Dale: TP53 and breast cancer. Hum. Mutat. 21, 292-300 (2003)
43. T. Sorlie, C. M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. B. Eisen, R. M. van de, S. S. Jeffrey, T. Thorsen, H. Quist, J. C. Matese, P. O. Brown, D. Botstein, L. P. Eystein, and A. L. Borresen-Dale: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A 98, 10869-10874 (2001) (Pubitemid 32878711)
44. K. Al-Kuraya, P. Schraml, J. Torhorst, C. Tapia, B. Zaharieva, H. Novotny, H. Spichtin, R. Maurer, M. Mirlacher, O. Kochli, M. Zuber, H. Dieterich, F. Mross, K. Wilber, R. Simon, and G. Sauter: Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 64, 8534-8540 (2004) (Pubitemid 39552065)
45. D. Danovi, E. Meulmeester, D. Pasini, D. Migliorini, M. Capra, R. Frenk, G. P. de, S. Francoz, P. Gasparini, A. Gobbi, K. Helin, P. G. Pelicci, A. G. Jochemsen, and J. C. Marine: Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell Biol. 24, 5835-5843 (2004) (Pubitemid 38787968)
46. D. Danovi, E. Meulmeester, D. Pasini, D. Migliorini, M. Capra, R. Frenk, G. P. de, S. Francoz, P. Gasparini, A. Gobbi, K. Helin, P. G. Pelicci, A. G. Jochemsen, and J. C. Marine: Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity. Mol. Cell Biol. 24, 5835-5843 (2004) (Pubitemid 38787968)
47. J. Rauta, E. L. Alarmo, P. Kauraniemi, R. Karhu, T. Kuukasjarvi, and A. Kallioniemi: The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res. Treat. 95, 257-263 (2006)
48. S. Llanos, P. A. Clark, J. Rowe, and G. Peters: Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat. Cell Biol. 3, 445-452 (2001) (Pubitemid 32422079)
49. F. J. Stott, S. Bates, M. C. James, B. B. McConnell, M. Starborg, S. Brookes, I. Palmero, K. Ryan, E. Hara, K. H. Vousden, and G. Peters: The alternative product from the human CDKN2A locus, p14 (ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17, 5001-5014 (1998) (Pubitemid 28408466)
50. T. Kamijo, J. D. Weber, G. Zambetti, F. Zindy, M. F. Roussel, and C. J. Sherr: Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. U. S. A 95, 8292-8297 (1998) (Pubitemid 28326106)
51. J. Pomerantz, N. Schreiber-Agus, N. J. Liegeois, A. Silverman, L. Alland, L. Chin, J. Potes, K. Chen, I. Orlow, H. W. Lee, C. Cordon-Cardo, and R. A. DePinho: The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92, 713-723 (1998) (Pubitemid 28155311)
52. T. Kamijo, F. Zindy, M. F. Roussel, D. E. Quelle, J. R. Downing, R. A. Ashmun, G. Grosveld, and C. J. Sherr: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 91, 649-659 (1997) (Pubitemid 27513656)
53. D. A. Haber: Splicing into senescence: the curious case of p16 and p19ARF. Cell 91, 555-558 (1997) (Pubitemid 27513645)
54. D. Katayose, J. Gudas, H. Nguyen, S. Srivastava, K. H. Cowan, and P. Seth: Cytotoxic effects of adenovirusmediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin. Cancer Res. 1, 889-897 (1995)
55. A. Ventura, D. G. Kirsch, M. E. McLaughlin, D. A. Tuveson, J. Grimm, L. Lintault, J. Newman, E. E. Reczek, R. Weissleder, and T. Jacks: Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007) (Pubitemid 46232887)
56. W. Xue, L. Zender, C. Miething, R. A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo, and S. W. Lowe: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007) (Pubitemid 46232886)
57. C. P. Martins, L. Brown-Swigart, and G. I. Evan: Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006) (Pubitemid 44960417)
58. R. Honda, H. Tanaka, and H. Yasuda: Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420, 25-27 (1997) (Pubitemid 28037193)
59. R. Honda and H. Yasuda: Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19, 1473-1476 (2000) (Pubitemid 30171179)
60. J. Momand, G. P. Zambetti, D. C. Olson, D. George, and A. J. Levine: The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69, 1237-1245 (1992)
61. S. M. Picksley and D. P. Lane: The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53? Bioessays 15, 689-690 (1993)
62. J. D. Oliner, J. A. Pietenpol, S. Thiagalingam, J. Gyuris, K. W. Kinzler, and B. Vogelstein: Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 362, 857-860 (1993) (Pubitemid 23132165)
63. J. Chen, V. Marechal, and A. J. Levine: Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13, 4107-4114 (1993) (Pubitemid 23187639)
64. J. Lin, J. Chen, B. Elenbaas, and A. J. Levine: Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes Dev. 8, 1235-1246 (1994) (Pubitemid 24163450)
65. S. M. Picksley, B. Vojtesek, A. Sparks, and D. P. Lane: Immunochemical analysis of the interaction of p53 with MDM2;-fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9, 2523-2529 (1994) (Pubitemid 24254027)
66. P. Chene, J. Fuchs, I. Carena, P. Furet, and C. Garcia-Echeverria: Study of the cytotoxic effect of a peptidic inhibitor of the p53-hdm2 interaction in tumor cells. FEBS Lett. 529, 293-297 (2002)
67. J. W. Harbour, L. Worley, D. Ma, and M. Cohen: Transducible peptide therapy for uveal melanoma and retinoblastoma. Arch. Ophthalmol. 120, 1341-1346 (2002) (Pubitemid 36105439)
68. L. T. Vassilev: Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3, 419-421 (2004) (Pubitemid 40278226)
69. K. Kojima, M. Konopleva, T. McQueen, S. O'Brien, W. Plunkett, and M. Andreeff: Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 108, 993-1000 (2006) (Pubitemid 44154636)
70. J. R. Elison, D. Cobrinik, N. Claros, D. H. Abramson, and T. C. Lee: Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch. Ophthalmol. 124, 1269-1275 (2006) (Pubitemid 44379861)
71. C. Tovar, J. Rosinski, Z. Filipovic, B. Higgins, K. Kolinsky, H. Hilton, X. Zhao, B. T. Vu, W. Qing, K. Packman, O. Myklebost, D. C. Heimbrook, and L. T. Vassilev: Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. U. S. A 103, 1888-1893 (2006) (Pubitemid 43228788)
72. G. A. LaRusch, M. W. Jackson, J. D. Dunbar, R. S. Warren, D. B. Donner, and L. D. Mayo: Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res. 67, 450-454 (2007) (Pubitemid 46192180)
73. J. Zhao, M. Wang, J. Chen, A. Luo, X. Wang, M. Wu, D. Yin, and Z. Liu: The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure. Cancer Lett. 183, 69-77 (2002) (Pubitemid 34607353)
74. R. Stoll, C. Renner, S. Hansen, S. Palme, C. Klein, A. Belling, W. Zeslawski, M. Kamionka, T. Rehm, P. Muhlhahn, R. Schumacher, F. Hesse, B. Kaluza, W. Voelter, R. A. Engh, and T. A. Holak: Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53. Biochemistry 40, 336-344 (2001) (Pubitemid 32061981)
75. S. K. Kumar, E. Hager, C. Pettit, H. Gurulingappa, N. E. Davidson, and S. R. Khan: Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J. Med. Chem. 46, 2813-2815 (2003) (Pubitemid 36775907)
76. C. Garcia-Echeverria, P. Chene, M. J. Blommers, and P. Furet: Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem. 43, 3205-3208 (2000)
77. S. J. Duncan, S. Gruschow, D. H. Williams, C. McNicholas, R. Purewal, M. Hajek, M. Gerlitz, S. Martin, S. K. Wrigley, and M. Moore: Isolation and structure elucidation of Chlorofusin, a novel p53-MDM2 antagonist from a Fusarium sp. J. Am. Chem. Soc. 123, 554-560 (2001) (Pubitemid 32105997)
78. N. Issaeva, P. Bozko, M. Enge, M. Protopopova, L. G. Verhoef, M. Masucci, A. Pramanik, and G. Selivanova: Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321-1328 (2004) (Pubitemid 40022713)
79. N. M. Dean and C. F. Bennett: Antisense oligonucleotide-based therapeutics for cancer. Oncogene 22, 9087-9096 (2003) (Pubitemid 38121709)
80. R. Zhang, H. Wang, and S. Agrawal: Novel antisense anti-MDM2 mixed-backbone oligonucleotides: proof of principle, in vitro and in vivo activities, and mechanisms. Curr. Cancer Drug Targets. 5, 43-49 (2005) (Pubitemid 40321799)
81. L. Chen, S. Agrawal, W. Zhou, R. Zhang, and J. Chen: Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc. Natl. Acad. Sci. U. S. A 95, 195-200 (1998) (Pubitemid 28103930)
82. L. Chen, W. Lu, S. Agrawal, W. Zhou, R. Zhang, and J. Chen: Ubiquitous induction of p53 in tumor cells by antisense inhibition of MDM2 expression. Mol. Med. 5, 21-34 (1999) (Pubitemid 29282094)
83. R. Zhang and H. Wang: Antisense oligonucleotide inhibitors of MDM2 oncogene expression. Methods Mol. Med. 85, 205-222 (2003)
84. H. Wang, S. Wang, L. Nan, D. Yu, S. Agrawal, and R. Zhang: Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms. Int. J. Oncol. 20, 745-752 (2002)
85. H. Wang, X. Zeng, P. Oliver, L. P. Le, J. Chen, L. Chen, W. Zhou, S. Agrawal, and R. Zhang: MDM2 oncogene as a target for cancer therapy: An antisense approach. Int. J. Oncol. 15, 653-660 (1999)
86. A. Zaika, N. Marchenko, and U. M. Moll: Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation. J. Biol. Chem. 274, 27474-27480 (1999)
87. J. E. Chipuk, U. Maurer, D. R. Green, and M. Schuler: Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4, 371-381 (2003) (Pubitemid 37491098)
88. Y. Li, Y. Mao, P. W. Brandt-Rauf, A. C. Williams, and R. L. Fine: Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Mol. Cancer Ther. 4, 901-909 (2005) (Pubitemid 40909072)
89. K. Lee, T. Wang, A. J. Paszczynski, and S. S. Daoud: Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells. Biochem. Biophys. Res. Commun. 349, 1117-1124 (2006) (Pubitemid 44380211)
90. V. J. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K. G. Wiman, and G. Selivanova: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282-288 (2002) (Pubitemid 34250107)
91. V. J. Bykov, N. Issaeva, A. Shilov, M. Hultcrantz, E. Pugacheva, P. Chumakov, J. Bergman, K. G. Wiman, and G. Selivanova: Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8, 282-288 (2002) (Pubitemid 34250107)
92. B. A. Foster, H. A. Coffey, M. J. Morin, and F. Rastinejad: Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510 (1999)
93. C. K. Ho and G. Li: Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis. Br. J. Dermatol. 153, 900-910 (2005) (Pubitemid 41540753)
94. Y. Luu and G. Li: The p53-stabilizing compound CP-31398 enhances ultraviolet-B-induced apoptosis in a human melanoma cell line MMRU. J. Invest Dermatol. 119, 1207-1209 (2002) (Pubitemid 35430502)
95. R. Takimoto, W. Wang, D. T. Dicker, F. Rastinejad, J. Lyssikatos, and W. S. El-Deiry: The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol. Ther. 1, 47-55 (2002)
96. W. Wang, R. Takimoto, F. Rastinejad, and W. S. El-Deiry: Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol. Cell Biol. 23, 2171-2181 (2003) (Pubitemid 36278825)
97. C. K. Ho and G. Li: Mutant p53 melanoma cell lines respond differently to CP-31398-induced apoptosis. Br. J. Dermatol. 153, 900-910 (2005) (Pubitemid 41540753)
98. Y. Luu and G. Li: The p53-stabilizing compound CP-31398 enhances ultraviolet-B-induced apoptosis in a human melanoma cell line MMRU. J. Invest Dermatol. 119, 1207-1209 (2002) (Pubitemid 35430502)
99. R. Takimoto, W. Wang, D. T. Dicker, F. Rastinejad, J. Lyssikatos, and W. S. El-Deiry: The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol. Ther. 1, 47-55 (2002)
100. B. A. Foster, H. A. Coffey, M. J. Morin, and F. Rastinejad: Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507-2510 (1999)
101. V. J. Bykov, N. Issaeva, N. Zache, A. Shilov, M. Hultcrantz, J. Bergman, G. Selivanova, and K. G. Wiman: Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J. Biol. Chem. 280, 30384-30391 (2005) (Pubitemid 41216221)
102. Y. Zhao, S. Lu, L. Wu, G. Chai, H. Wang, Y. Chen, J. Sun, Y. Yu, W. Zhou, Q. Zheng, M. Wu, G. A. Otterson, and W. G. Zhu: Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide induces expression of p21 (Waf1/Cip1). Mol. Cell Biol. 26, 2782-2790 (2006)
103. M. V. Blagosklonny, S. Trostel, G. Kayastha, Z. N. Demidenko, L. T. Vassilev, L. Y. Romanova, S. Bates, and T. Fojo: Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res. 65, 7386-7392 (2005) (Pubitemid 41161272)
104. C. P. Martins, L. Brown-Swigart, and G. I. Evan: Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006) (Pubitemid 44960417)
105. A. Ventura, D. G. Kirsch, M. E. McLaughlin, D. A. Tuveson, J. Grimm, L. Lintault, J. Newman, E. E. Reczek, R. Weissleder, and T. Jacks: Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007) (Pubitemid 46232887)
106. W. Xue, L. Zender, C. Miething, R. A. Dickins, E. Hernando, V. Krizhanovsky, C. Cordon-Cardo, and S. W. Lowe: Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007) (Pubitemid 46232886)
107. H. B. Gaspar and A. J. Thrasher: Gene therapy for severe combined immunodeficiencies. Expert. Opin. Biol. Ther. 5, 1175-1182 (2005) (Pubitemid 41243353)
108. S. Su, A. Watanabe, M. Yamamoto, E. Nakajima, K. Miyake, and T. Shimada: Mutations in p53 cDNA sequence introduced by retroviral vector. Biochem. Biophys. Res. Commun. 340, 567-572 (2006) (Pubitemid 43024119)
109. D. W. Cai, T. Mukhopadhyay, Y. Liu, T. Fujiwara, and J. A. Roth: Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum. Gene Ther. 4, 617-624 (1993) (Pubitemid 24305758)
110. G. S. Watts, M. M. Oshiro, D. J. Junk, R. J. Wozniak, S. Watterson, F. E. Domann, and B. W. Futscher: The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. Neoplasia. 6, 187-194 (2004) (Pubitemid 38657074)
111. Z. Z. Lu, F. Ni, Z. B. Hu, L. Wang, H. Wang, Q. W. Zhang, W. R. Huang, C. T. Wu, and L. S. Wang: Efficient gene transfer into hematopoietic cells by a retargeting adenoviral vector system with a chimeric fiber of adenovirus serotype 5 and 11p. Exp. Hematol. 34, 1171-1182 (2006)
112. D. S. Bangari and S. K. Mittal: Current strategies and future directions for eluding adenoviral vector immunity. Curr. Gene Ther. 6, 215-226 (2006)
113. D. T. Rein, M. Breidenbach, and D. T. Curiel: Current developments in adenovirus-based cancer gene therapy. Future. Oncol. 2, 137-143 (2006)
114. J. M. Kaplan: Adenovirus-based cancer gene therapy. Curr. Gene Ther. 5, 595-605 (2005) (Pubitemid 43009504)
115. G. S. Watts, M. M. Oshiro, D. J. Junk, R. J. Wozniak, S. Watterson, F. E. Domann, and B. W. Futscher: The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. Neoplasia. 6, 187-194 (2004) (Pubitemid 38657074)
116. J. Yu, L. Zhang, P. M. Hwang, C. Rago, K. W. Kinzler, and B. Vogelstein: Identification and classification of p53-regulated genes. Proc. Natl. Acad. Sci. U. S. A 96, 14517-14522 (1999) (Pubitemid 30000682)
117. J. A. Eastham, W. Grafton, C. M. Martin, and B. J. Williams: Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J. Urol. 164, 814-819 (2000) (Pubitemid 30637639)
118. M. Giuliano, A. Catalano, L. Strizzi, G. Vianale, M. Capogrossi, and A. Procopio: Adenovirus-mediated wildtype p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int. J. Mol. Med. 5, 591-596 (2000)
119. D. I. Gabrilovich: INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert. Opin. Biol. Ther. 6, 823-832 (2006) (Pubitemid 44174214)
120. S. G. Swisher, J. A. Roth, R. Komaki, J. Gu, J. J. Lee, M. Hicks, J. Y. Ro, W. K. Hong, J. A. Merritt, K. Ahrar, N. E. Atkinson, A. M. Correa, M. Dolormente, L. Dreiling, A. K. El-Naggar, F. Fossella, R. Francisco, B. Glisson, S. Grammer, R. Herbst, A. Huaringa, B. Kemp, F. R. Khuri, J. M. Kurie, Z. Liao, T. J. McDonnell, R. Morice, F. Morello, R. Munden, V. Papadimitrakopoulou, K. M. Pisters, J. B. Putnam, Jr., A. J. Sarabia, T. Shelton, C. Stevens, D. M. Shin, W. R. Smythe, A. A. Vaporciyan, G. L. Walsh, and M. Yin: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin. Cancer Res. 9, 93-101 (2003) (Pubitemid 36109720)
121. L. L. Pisters, C. A. Pettaway, P. Troncoso, T. J. McDonnell, L. C. Stephens, C. G. Wood, K. A. Do, S. M. Brisbay, X. Wang, E. A. Hossan, R. B. Evans, C. Soto, M. G. Jacobson, K. Parker, J. A. Merritt, M. S. Steiner, and C. J. Logothetis: Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin. Cancer Res. 10, 2587-2593 (2004) (Pubitemid 38509130)
122. J. Guo and H. Xin: Chinese gene therapy. Splicing out the West? Science 314, 1232-1235 (2006) (Pubitemid 44846373)
123. J. Flint and T. Shenk: Viral transactivating proteins. Annu. Rev. Genet. 31, 177-212 (1997) (Pubitemid 28023706)
124. S. E. de, M. E. McCurrach, F. Zindy, S. Y. Shieh, G. Ferbeyre, A. V. Samuelson, C. Prives, M. F. Roussel, C. J. Sherr, and S. W. Lowe: E1A signaling to p53 involves the p19 (ARF) tumor suppressor. Genes Dev. 12, 2434-2442 (1998) (Pubitemid 28371362)
125. W. S. El-Deiry, T. Tokino, V. E. Velculescu, D. B. Levy, R. Parsons, J. M. Trent, D. Lin, W. E. Mercer, K. W. Kinzler, and B. Vogelstein: WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993) (Pubitemid 23346378)
126. T. Miyashita and J. C. Reed: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80, 293-299 (1995)
127. C. C. Kao, P. R. Yew, and A. J. Berk: Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 179, 806-814 (1990)
128. P. R. Yew and A. J. Berk: Inhibition of p53 transactivation required for transformation by adenovirus early 1B protein. Nature 357, 82-85 (1992)
129. P. R. Yew, X. Liu, and A. J. Berk: Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev. 8, 190-202 (1994)
130. M. Dobbelstein, J. Roth, W. T. Kimberly, A. J. Levine, and T. Shenk: Nuclear export of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a revlike signal sequence. EMBO J. 16, 4276-4284 (1997) (Pubitemid 27298180)
131. W. T. Steegenga, N. Riteco, A. G. Jochemsen, F. J. Fallaux, and J. L. Bos: The large E1B protein together with the E4orf6 protein target p53 for active degradation in adenovirus infected cells. Oncogene 16, 349-357 (1998) (Pubitemid 28052289)
132. D. D. Barker and A. J. Berk: Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107-121 (1987) (Pubitemid 17013653)
133. J. R. Bischoff, D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376 (1996) (Pubitemid 26353341)
134. J. R. Bischoff, D. H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J. A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376 (1996) (Pubitemid 26353341)
135. C. Heise, A. Sampson-Johannes, A. Williams, F. McCormick, D. D. Von Hoff, and D. H. Kirn: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639-645 (1997) (Pubitemid 27264973)
136. M. Milas, D. Yu, A. Lang, T. Ge, B. Feig, A. K. El-Naggar, and R. E. Pollock: Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity. Cancer Gene Ther. 7, 422-429 (2000) (Pubitemid 30210409)
137. H. Miyake, I. Hara, S. Hara, S. Arakawa, and S. Kamidono: Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated P53 gene transfer in human bladder cancer model. Urology 56, 332-336 (2000) (Pubitemid 30495606)
138. E. Vattemi and P. P. Claudio: Adenoviral gene therapy in head and neck cancer. Drug News Perspect. 19, 329-337 (2006) (Pubitemid 44409884)
139. T. R. Reid, S. Freeman, L. Post, F. McCormick, and D. Y. Sze: Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther. 12, 673-681 (2005) (Pubitemid 41045565)
140. X. Y. Liu: Targeting gene-virotherapy of cancer and its prosperity. Cell Res. 16, 879-886 (2006) (Pubitemid 44764197)
141. C. P. Martins, L. Brown-Swigart, and G. I. Evan: Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006) (Pubitemid 44960417)
142. A. Ventura, D. G. Kirsch, M. E. McLaughlin, D. A. Tuveson, J. Grimm, L. Lintault, J. Newman, E. E. Reczek, R. Weissleder, and T. Jacks: Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007) (Pubitemid 46232887)
143. W. Xue, L. Zender, C. Miething, R. A. Dickins, E. Hernando, V.
144. I. Ringshausen, C. C. O'Shea, A. J. Finch, L. B. Swigart, and G. I. Evan: Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 10, 501-514 (2006) (Pubitemid 44854749)
145. M. A. Christophorou, I. Ringshausen, A. J. Finch, L. B. Swigart, and G. I. Evan: The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 443, 214-217 (2006) (Pubitemid 44387609)
146. F. Murray-Zmijewski, D. P. Lane, and J. C. Bourdon: p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death. Differ. 13, 962-972 (2006)
147. C. L. Wei, Q. Wu, V. B. Vega, K. P. Chiu, P. Ng, T. Zhang, A. Shahab, H. C. Yong, Y. Fu, Z. Weng, J. Liu, X. D. Zhao, J. L. Chew, Y. L. Lee, V. A. Kuznetsov, W. K. Sung, L. D. Miller, B. Lim, E. T. Liu, Q. Yu, H. H. Ng, and Y. Ruan: A global map of p53 transcription-factor binding sites in the human genome. Cell 124, 207-219 (2006) (Pubitemid 43069320)
148. J. Yu, L. Zhang, P. M. Hwang, C. Rago, K. W. Kinzler, and B. Vogelstein: Identification and classification of p53-regulated genes. Proc. Natl. Acad. Sci. U. S. A 96, 14517-14522 (1999) (Pubitemid 30000682)
149. R. H. Weiss, D. Marshall, L. Howard, A. M. Corbacho, A. T. Cheung, and E. T. Sawai: Suppression of breast cancer growth and angiogenesis by an antisense oligodeoxynucleotide to p21 (Waf1/Cip1). Cancer Lett. 189, 39-48 (2003) (Pubitemid 35351518)
150. A. V. Gudkov and E. A. Komarova: Prospective therapeutic applications of p53 inhibitors. Biochem. Biophys. Res. Commun. 331, 726-736 (2005) (Pubitemid 40615504)